Roche to acquire Poseida Therapeutics for $1.5bn.

Roche, a Swiss multinational holding healthcare company, agreed to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company, for $1.5bn. “This exciting acquisition will allow us to drive further progress in allogeneic cell therapy while leveraging the successful existing partnership with Poseida. We are very encouraged by the early clinical data, and this acquisition builds on our joint progress to catalyse the development of potentially first and best-in-class cell therapies in oncology, immunology and neurology,” Levi Garraway, Roche Head of Product Development and Chief Medical Officer.